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The Dz dopamine receptor is known to be functionally coupled when expressed in CHO cells, whereas the effector systems for the D, dopamine 
receptor remain unclear. A chimeric, human D,/D2 receptor (hD,/D2) was constructed containing the third mtracellular loop region of the D, 
receptor. CHO cells stably expressing the D?, D,. or hD,/D? receptors were created and the pharmacology of the receptors was exammed. The 
chimeric hD,/D? receptor retained D,-like affinities for dopaminergic ligands. However, in contrast to the Dz receptor netther the D, receptor nor 
the hD,/D, receptor could functionally couple to the adenylate cyclase or arachidomc acid release mechanisms 
Dopamme receptor. Signal transductton: Functional coupling 
1. INTRODUCTION 
Dopamine has been known to be an important neuro- 
transmitter in the central nervous system for many 
years. Dopamine receptors are particularly interesting 
because of their apparent involvement in the aetiology 
of Parkinson’s disease and schizophrenia [l-3]. Until 
recently, dopamine receptors were subdivided into two 
classes (D, and D,) based upon their pharmacological 
properties [4]. The advent of gene cloning techniques 
has so far allowed the identification of five dopamine 
receptors designated D, to D, [5-l 11. D, and D5 dopam- 
ine receptors demonstrate properties similar to the 
pharmacologically defined D, dopamine receptor and 
are coupled to activation of adenylate cyclase [12], 
whereas the D2, D,, and D, dopamine receptors are 
more closely related to the classical D, dopamine recep- 
tor [8-lo]. All of these cloned dopamine receptors con- 
tain the seven putative transmembrane regions charac- 
teristic of G protein-coupled receptors [13]. When 
expressed in CHO (Chinese hamster ovary) cells the 
human and rat D, dopamine receptors displayed similar 
affinities to their D, counterparts for dopamine antago- 
nists [9,14,15]. However, D, dopamine receptors dem- 
onstrated much higher affinities for some dopamine ag- 
onists (e.g. dopamine, quinpirole) than D, dopamine 
receptors. In contrast to the human and rat D2 recep- 
tors. which can mediate an inhibitory adenylate cyclase 
response and arachidonic acid release. both human and 
rat D, dopamine receptors did not couple efficiently to 
these signal transduction mechanisms in CHO cells 
[9,14,15]. 
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The putative third cytoplasmic loop of G protein- 
linked receptors has been implicated as being important 
for interacting with the G proteins required for effector 
coupling. In fact, a previous study examined a chimeric 
D, dopamine/ml muscarinic receptor in which the third 
intracellular loop region of the hD, receptor had been 
replaced by the equivalent region of the ml muscarinic 
receptor [16]. The resulting chimeric receptor mediated 
an increase in intracellular calcium levels in response to 
dopamine, an effect not found with the D? dopamine 
receptor itself. In this work, we have examined the phar- 
macology of a chimeric receptor (hD,/D,) in which the 
third intracellular loop region (i3) of the apparently 
uncoupled human D, dopamine receptor (hD,) has been 
replaced with the analogous region of the functional 
human D, dopamine receptor (hD,). 
2. MATERIALS AND METHODS 
2 I. Receptor clones 
Abbreviutions. hD,. human Dz dopamme receptor; hD,. human Dz DNA and a stably transfected CHO-Kl cell line for the human D, 
dopamine receptor; hD,/D2, human chimeric D,/D2 dopamine recep- dopamine receptor were obtained from Sokoloff et al. (INSERM). Dz 
tor; GTP. guanosine triphosphate; CAMP, adenosine 3’,5’-cychc cDNA clones were obtained usmg PCR techmques [20]. Based on the 
monophosphate. published sequence of the human D_ ,B receptor [17] the followmg 
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oligonucleotides were synthesized: DRI, S’-TTTTGAATTCGCCCT- 
GATGGATCCACTG-3’: DR3, 5”-TTTTCTCGAGAAGAAGAG- 
GAGGCCGATC-3’ and DR3, Y-TTTTCTCGAGTGGGAAG- 
CAGGCTGCTCTGT-3’ cDNA was prepared from I pg of human 
brain mRNA (Clonetech Inc.) and used as a template for two sequen- 
tial rounds of PCR. Both rounds of PCR used the followmg cycle 
conditions, 1 mm at 95”C/l mm at 56W2.5 mm at 72°C. The first 
round utilized primers DR 1 and DR2 and the second used DR I and 
DR3. The 1,320-bp product of this PCR amplification was restriction 
digested with EcoRI and X/WI and subcloned mto the expre,slon 
vector pcDNAlneo (Invltrogen Corp.) and its Identity confirmed by 
DNA sequencing Chimerlc hD,/DZ DNA was generated m three 
stages usmg PCR techniques. Cloned hD, DNA m pBluescrlpt (Strat- 
agene) was used as template to generate PCR products containing the 
first 5 transmembrane regions of the hD, clone (Primers CD1 and 
CD2). CD1 generated a PCR product containing part of the multiple 
clonmg site of pBluescript (including a Hind111 site) and CD2 con- 
tamed a BanzHI sIteJust downstream of a @PI site. This PCR product 
(PCR I) was subcloned mto pBluescnpt after digestion with Hind111 
and BumHI. Next, PCR 2 contaimng transmembrane regions six and 
seven of the hD, clone was generated using primers CD3 and CD4 
CD3 contained a BnrnHI Site upstream of a NIleI site and CD4 gener- 
ated a PCR product contammg part of the pBluescrlpt multIpIe clon- 
ing site (includmg a spe1 site). After digestion with BUFVHI and SpeI, 
PCR 2 was subcloned mto the PCR 1 contammg vector digested with 
Bun7HI and XhaI This generated a plasmid containing the seven 
transmembrane regions of the hD, receptor but missmg the third 
intracellular loop region (i3). This construct also contained SpeI and 
NhrI restrlction sites sultable for inserting DNA m the i3 region PCR 
3 was carried out using CD5 and CD6 primers and hDZ DNA as a 
template and generated a product containing the 13 region of the hD2 
receptor and SpeI and Nllel at the 5’ and 3’ ends, respectively PCR 
3 was subcloned mto the vector contaming PCR 1 and 2 to generate 
the chlmeric hD,/D, receptor. The construct was sequenced to confirm 
Its structure and was then subcloned into the HindIIIINutl sites of 
pcDNAlneo (Invitrogen) for use m subsequent transfectlon studies. 
PCR reactions were carried out for 1 mm at 94”C/l min at 55”C/2 min 
at 72°C for 20 cycles. The primers used were as follows: CD]. 5’- 
ATACGACTCACTATAGGGCGAATTG-3’. CDZ. 5’-ATGGATC- 
CTGGCATAGACTAGTACAGTCA-3’. CD3. 5’-ATGGATCCAC- 
TTCGGGAGAAGAAGGCTAGCCA-3’. CD4,5’- AACCCTCAC- 
TAAAGGGAACAAAAGC-3’, CD5, 5’. CCCTTCATTGTCACC- 
CTACTAGTCTA-3’, CD6, S-CGAGCATCTGGCTAGCTTTCTT- 
CTCCT-3’ 
2.2. Cell culture und tran.&mn 
Chmese hamster ovary (CHO) cells (ATCC CCL 61) were grown 
at 37°C in a humidified atmosphere of 95% air/5% CO, in Iscove’s 
Modified Dulbecco’s Medium (Glbco) supplemented with 10% foetal 
bovine serum, 1% glutamine and HT media supplement. Stably tran5- 
fected cell hnes were obtamed by transfecting the mammalian expres- 
sion vector pcDNAlneo (Invitrogen) contammg the appropriate 
dopamine receptor cDNA mto CHO-K 1 cells by a standard calcium 
phosphate method (Cullen 1987). Transfected cells were selected for 
their resistance to the antiblotlc G418 and assayed for their ablhty to 
bind [“51]iodosulplride. Of I8 individual chimera clones tested. I7 
demonstrated specific radloligand bmding. 
2.3. Rudmligmd bvuilng 
2.3. I. Iodosulpride bindmg 
Clonal cell lines stably expressing dopamine receptors were har- 
vested in PBS and then Iysed by polytronmg m 10 mM Tris-HCI pH 
7.4 containing 5 mM MgSO, for 10 s on ice. Membranes were centn- 
fuged at 50.000 x g for I5 mm at 4°C and the resulting pellet resus- 
pended in assay buffer (20 mM HEPES Krebs buffer pH 7.4 contain- 
ing 118 mM NaCl. 4.7 mM KCI, 1.2 mM MgSO,. 5 mM NaHCO,. 
1 2 mM KH,PO,. 2.5 mM CaCI?. 10,~M pargyhne and 0 1% ascorbic 
acid) at 20 mg/ml wet weight. Scatchard analysis and displacement 
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studies were carried out on chimeric clone 34. Incubations were in the 
presence of 0.05-l nM [“‘I]lodosulplrlde or 0.2 nM for displacement 
studies and were imtlated by the ad&Ion of 100-200 /g protein to a 
final assay volume of 0.1 ml. The incubation was for 30 min at 30°C 
and was terminated bq rapid filtration over GF/B filters presoaked m 
0.3% PEI and washed with 10 ml ice cold 0.9% NaCl Specific bindmg 
was defined by I ,uM haloperidol and radloactivity determmed by 
liquid scintillation spectrometry. 
2.32. N-0437 binding 
Cells were prepared as described above. Washed membranes were 
resuspended at 300 mg/ml m 20 mM HEPES buffer pH 7.4 containing 
5 mM MgSO, and 0.1% ascorbate. Binding was determined using 1 
nM [‘H]N-0437 and non-speafic bindmg determined with 1 ,uM ha- 
loperidol. Incubations were for times up to 60 min at 30°C and were 
terminated by filtration over GFlC filters presoaked in 0.3% PEI. 
Guanine nucleotlde sensltlvlty was determined in the presence and 
absence of 100 ,uM GTP-r-S (Sigma). Eight clones representing low, 
medium and high levels of expression were examined. 
Adenylate cyclase, arachtdonic acid release and phosphatidyl inosl- 
tol hydrolysis measurements were carried out as described previously 
P81. 
3. RESULTS AND DISCUSSION 
3.1. Receptor expression, ligund binding and GTP slliffs 
Fig. 1 shows a schematic diagram of the chimeric 
hD,/D? receptor that was constructed. The construction 
was carried out in three parts using PCR methodology 
(see section 2). Firstly, a hD, dopamine receptor which 
did not contain the third cytoplasmic loop was made. 
This construct was made such that it had convenient 
restriction sites for the insertion of the hDz receptor i3 
region (or any other loop region with suitable restriction 
sites). Secondly, the hD, loop region was inserted and 
the fidelity of the construct was confirmed by DNA 
sequencing. The introduction of the NIleI site at the 
boundary of the third cytoplasmic loop and transmem- 
brane region VI resulted in a threonine to serine point 
mutation (see Fig. 1). However, this is a conservative 
substitution in a residue that is not conserved through 
all dopamine receptors (e.g. it is a methionine in D, 
receptors and a leucine in D,) which would not be ex- 
pected to change the pharmacology of the receptor. 
Thirdly, the chimeric construct was subcloned into the 
expression vector pcDNAlneo to generate the plasmid 
pD,,,neo which was used in subsequent transfection 
studies. The hD2,rhort, receptor cDNA was isolated using 
PCR techniques from human brain cDNA. Its identity 
was confirmed by DNA sequencing and it was subse- 
quently cloned into pcDNA1neo and used for transfec- 
tion studies. Preliminary studies demonstrated that 
when pD,,,neo or pD,neo was used to transiently trans- 
feet HEK 293 (human embryonic kidney) cells the re- 
sulting membranes showed considerable specific bind- 
ing for the dopaminergic ligand [“51]iodosulpiride (data 
not shown). We then created stable cell lines expressing 
the chimeric hD,/D? or the hD, receptors by trans- 
fecting CHO-Kl cells with pD,,,neo and pD,neo. re- 
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a Dg Receptor 
a D, Receptor 
Fig. 1. A schematic diagram of the chimenc receptor Amino acids (m the single letter code) up to and after those m black circles are derived from 
the hD, receptor. Amino acids in between are derived from the hDZ receptor. Construction of the chimera IS described in se&Ion 2. Amino acids 
m half black and white circles represent the junctions of the chimera and are common to the hD, and hD, receptors. The cross-hatched senne (S) 
residue IS a point mutation introduced m the construction of the chlmera to generate the convement .SpeI site. 
spectively. Transfected cells were selected for G418 re- 
sistance. CHO-Kl cells were chosen because they do not 
express endogenous dopamine receptors and because 
the hDz receptor is functionally coupled in this cell line 
[14,15]. Of 18 individual hD,/D, clonal lines examined, 
17 demonstrated specific [“‘Ijiodosulpiride binding. 
Eight of these positive clones representing low, medium 
and high levels of expression were studied for GTP 
sensitivity of agonist binding (see below). A chimeric 
clone, hD,/D,(34), expressing relatively high levels of 
receptor was used in radioligand studies. A typical hD, 
clone hD,CHO( 11) was used in all subsequent studies. 
The pharmacological binding profiles of the hDz, hD, 
and hD,/D, receptors expressed in CHO cells were com- 
pared to see what effect substituting the i3 region had 
upon the hD, receptor’s affinity for selected ligands. 
The affinity of [“‘I]iodosulpiride was determined for 
membranes made from cells expressing the hD,, hD, 
and hD,/D, receptors, respectively (data not shown). 
The K, for the hD, receptor was 0.26 nM (0.22, 0.33) 
(mean, range, II = 3) with a B,,, of 700 & 180 fmol/mg 
of protein, while for the hD, receptor the affinity was 
0.42 nM (0.38,0.47) (mean, range, II = 3) with a B,,, of 
290 + 33 fmol/mg of protein. These values are in good 
agreement with reported affinities. The hD,/D, (clone 
34) chimeric receptor displayed a slightly lower affinity 
of 0.7 nM (0.57, 0.88) with a B,,, of 370 fmol/mg of 
protein. The fidelity of the expressed receptors was fur- 
ther examined by testing the binding affinities of seven 
dopaminergic ligands in a competition binding assay 
with 0.2 nM [“?]iodosulpiride. The results are shown in 
Table I. All three receptor types tested displayed D,-like 
affinities for the D? antagonists (-)sulpiride and halop- 
eridol and low affinity for the D, antagonist, SCH- 
23390 as was expected. Like the hD, receptor, the hD,/ 
D, receptor displays higher affinity for hD, agonists 
such as dopamine and quinpirole compared to the hD, 
receptor, whereas other hD, agonists such as apomor- 
phine and bromocryptine did not show this selectivity. 
We conclude from this data that the chimeric receptor 
has maintained the pharmacological binding profile of 
the hD, receptor and we therefore proceeded to examine 
the functional coupling, if any, of these receptors. 
A characteristic of G protein coupled receptors is that 
the affinity of agonist binding for the receptors is re- 
duced by the presence of guanine nucleotides. We exam- 
ined (Fig. 2) the time course of binding of the dopamine 
agonist [3H]N-0437 to membranes prepared from the 
hD,, hD,, and hD,/D, cell lines in the presence and 
absence of the GTP analogue GTP-y-S (100 PM). The 
inhibition of [‘H]N-0437 binding by GTP-y-S is consis- 
tent with the hD, receptor interacting with a dissociable 
G protein in CHO cells (Fig. 2A). In contrast, neither 
the hD, (Fig. 2B) nor the hD,/D, (Fig. 2C) receptors 
demonstrate any inhibition of agonist binding in the 
presence of GTP-I/-S. Eight chimeric clones represent- 
ing low. medium and high levels of expression were 
tested, all of which specifically bound t3H]N-0437. 
However, no significant inhibition of agonist binding by 
GTP-y-S was observed in any of them. The results for 
clone hD,/D2(34) are depicted in Fig. 2C. Two recent 
reports have demonstrated a small rightward shift in 
dopamine competition of [‘251]iodosulpiride binding at 
the hD, receptor suggesting some level of interaction 
with a G protein in CHO cells [15,23]. The assay used 
in this study measures radiolabelled agonist binding di- 
rectly and is a more sensitive indicator of receptor-G 
protein interactions. None of these studies demon- 
strated functional coupling of the hD, receptor. 
3.2. Functionul coupling assays 
CHO cells expressing the hD,, hD3, and hD,/D, re- 
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ceptors, respectively, were also examined for functional 
coupling to inhibition of adenylate cyclase activity, ara- 
chidonic acid release and phosphatidyl inositol turn- 
over. Forskolin (10 PM) produced an increase in CAMP 
levels in all three cell lines. However, only in the hD, cell 
line (Fig. 3A) could this increase (from 0.19 ? 0.01 to 
13.9 & 1.1 pmol per well) be dose-dependently inhibited 
by dopamine. We have previously demonstrated that 
this inhibition was reversed by pretreatment with 1 ,uM 
haloperidol, and that dopamine ( 10 PM) could not in- 
hibit the forskolin-stimulated increase in CAMP levels 
in untransfected CHO cells, confirming that this effect 
is mediated by the transfected hD, dopamine receptors 
[14]. In the hD, (Fig. 3B) and hD,/D, (clone 34) (Fig. 
3C) cell lines forskolin (10 PM) also produced a stimu- 
lation in CAMP levels. however, this was not signifi- 
cantly altered by the presence of dopamine. Dopamine 
treatment alone did not modify the basal levels of 
CAMP in any of the cell lines (data not shown). Five 
individual cell lines expressing varying levels of the 
chimeric receptor were examined. A typical result is 
shown in Fig. 3C. These data confirm that the hD, 
receptor couples via an inhibitory adenylate cyclase ac- 
tivity in CHO cells and that the hD, does not. The lack 
of functional coupling of the chimeric receptor to this 
second messenger system suggests that inserting the D, 
i3 loop into the D, receptor is not sufficient to allow 
efficient coupling mediated by an appropriate G pro- 
tein. 
Dopamine has been shown to stimulate the release of 
arachidonic acid from hDz transfected cells in the pres- 
ence of either ATP or the tonophore A231 87 [14]. This 
effector system involves a different coupling mecha- 
nism, so the same five chimeric clones used in the 
adenylate cyclase experiments were tested for their abil- 
ity to stimulate arachidonic acid release. Our results 
showed that dopamine (1 PM) enhanced arachidonic 
Table I 
K, values (nM) for dopammergic ligands at the DzT D, and hD,/D? 
receptors 
Compound D, D, hD,ID, 
AgOtll.StS 
Dopamine 700 (600; 810) 25 (19. 34) 6.2 (2.7; 14) 
Quinpirole 580 (490. 690) 16 (14: 19) 7.9 (5.0; 12) 
Apomorphine 29 (24: 35) 14 (9.5: 21) 18 (13: 26) 
Bromocryptme 0 46 (0.27: 0.80) 2.2 ( 1. I; 4.2) 0.65 (0.37: 1.1) 
.kltcryonrsts 
(-)Sulptride 4.5 (3.6; 5.6) 8.0 (7.3: 8.8) 19 (I’; 30) 
Haloperidol 3.3 (1.5; 3.4) 14 (1.0: 1.9) 1.8 (1.0, 3.3) 
SCH-23390 560 (530. 590) 370 (330; 410) 270 (180: 410) 
Results are expressed as the geometrtc mean of the apparent inhibttton 
constant (KJ IC,, values were determmed m 3-8 independent expert- 
ments and converted usmg the Cheng-Prussoff equatton [22] Curves 
were generated from 8 points. each determmed m duplicate. Numbers 
m parentheses refer to the low and htgh error range. 
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Fig. 2. The effect of guanine nucleotidea on [lH]N-0437 bindmg 
Specttic bmding was determined as described in the method sectton m 
the presence (0) or absence (8:‘) of 100,~1M GTP-y-S at 0, 15, 30 and 
60 mm. (A) In CHO cells expressmg hD, receptors spectfic [jH]N- 
0437 bmding was stgmficantly decreased by the presence of GTP-Y-S. 
mdtcatmg couplmg to a G protem In contrast CHO cells expressing 
the hD, receptors (B) or the hDJDJ34) receptor (CI did not demon- 
strate any decrease of agonist binding. Each experiment was repeated 
at least three times and the results shown are from a typtcal expertment 
performed m quadruplicate. 
acid release from the hD, cell line in the presence of 1 
PM A23187 (Fig. 4A). This increase was reversed by 
pretreatment with 0.1 ,uM haloperidol. No increases in 
arachidonic acid release were observed following 
dopamine treatment of hD, or hD,/D, expressing cell 
lines (Fig. 4B and C). This again suggests that the chim- 
eric receptor does not functionally couple like the hDz 
receptor in CHO cells. 
It has been reported that dopamine can stimulate 
phosphatidyl inositol turnover when hD, receptors are 
expressed in certain cell lines [ 191. Accordingly. we ex- 
amined the effect of dopamine (0.01. 1. or 100 PM) on 
the hD,, hD,. and hD,/D, cell lines. Dopamine was 
unable to stimulate inositol monophosphatase levels in 
any of the cell lines (data not shown). Under the same 
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s 
Fig. 3. Coupling of human dopamine receptors to Inhibition of adenyl- 
ate cyclase activity. (A) Forskolin stlmulatlon of adenylate cyclase 
activity was inhibited by the activation of hDz receptors expressed in 
CHO cells in a dose-dependent manner. In contrast. CHO cells ex- 
pressing the hD, receptors (B). or the hD,/D,(34) receptor (0. did not 
demonstrate any mhlbltion of the response. Results are from a typrcal 
experiment performed m quadruphcate. Each experiment *as re- 
peated on at least three separate occasions. Values are expressed as 
CAMP levels per well in pmol. 
conditions carbachol (1 mM) produced a 6- to 7-fold 
stimulation in a CHO cell line stably expressing the 
human ml muscarinic receptor 1211. We conclude that 
neither the hD, nor the hD, receptors functionally cou- 
ple via phosphatidyl inositol turnover in CHO cells. 
3.3. Conclllsions 
There are several possible explanations of the appar- 
ent lack of functional coupling of the hD, dopamine 
receptor when expressed in CHO cells. One possibility 
is that there is no appropriate G protein present to 
mediate signal transduction in this cell line. We have 
reported elsewhere the effect of expressing the hD, re- 
ceptor in a variety of cell lines [ 14,181. A second possibil- 
ity is that the hD, receptor couples via an as yet unde- 
scribed mechanism, although this seems unlikely given 
the hD, receptor’s extensive homology with classical G 
protein-coupled receptors. A third possibility is that the 
hD, receptor is very tightly bound to an inappropriate 
C 
8000 
zz 
:: 
4000 
0 
L 
0 Control 
q 1pM Dopamne (Da) 
q IwM Halopendol (Hal) 
m 1pM A23187 
W A23187+Da 
q A231 87+Da+Hal 
hD,/D, 
Fig. 4. Couphng of human dopamme receptors to arachidomc acid 
release (A) Arachldomc acid release was potentlated by the activation 
of hD, receptors expressed in CHO cells after pretreatment with the 
calcium ionophore. A23187. This potentlatlon *as blocked by pre- 
treatment with haloperldol. In contrast CHO cells expressmg the 
human D, receptors (B) or the hD,/D1(34) receptors (C)did not dem- 
onstrate this potentlatlon 
G protein such that the receptor-G protein complex 
cannot dissociate. This latter explanation would ac- 
count for the apparent selectivity of the hD, receptor for 
certain agonists relative to the hD, receptor and would 
explain the lack of inhibition of agonist binding in the 
presence of guanine nucleotides. This study addresses 
the first and last of these possibilities. It is clear that the 
hD, receptor can functionally couple to the adenylate 
cyclase and arachidonic acid release systems in CHO 
cells [ 14.151, and that agonist binding to the hD, recep- 
tor in this cell line is modulated by the presence of 
guanine nucleotides. It is also well established that the 
i3 loop of G protein-coupled receptors is very important 
in determining G protein binding (e.g. [16]). Therefore, 
a chimeric hD, receptor containing the hD, i3 loop 
region may circumvent any problems associated with G 
protein specificity (the chimera should be able to bind 
to the same G protein that the hD, receptor utilizes). 
Similarly, such a chimera would be expected to mini- 
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mise the chances of a G protein being ‘stuck’ tightly to 
the receptor. Our initial binding data confirms that the 
chimeric receptor is expressed correctly in CHO cells 
and is able to bind dopaminergic ligands with an appro- 
priate pharmacology. The binding profile of the chi- 
mera is very similar to that of the hD, receptor. How- 
ever, the chimera does not behave as predicted in func- 
tional studies. There is no guanine nucleotide sensitivity 
of agonist binding and no evidence of functional cou- 
pling to conventional second messenger systems was 
detected. Thus, either other regions of the hD, receptor 
may influence G protein binding, or replacing only the 
third intracellular loop region is insufficient to allow 
interaction with the G protein(s) which couple the hD, 
receptor. Alternatively, and perhaps most interestingly, 
it may be that the hD, receptor does couple in an as yet 
undescribed way. Whatever the explanation, the sugges- 
tion that the hD, receptor constitutes an important tar- 
get for antipsychotic drugs awaits a convincing demon- 
stration that the D, receptor is the functional correlate 
of a central nervous system dopamine receptor. 
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